WIN 2022 Program

INTEGRATING GENOMICS AND TRANSCRIPTOMICS TO RESHAPE PRECISION ONCOLOGY:
A WINNING STRATEGY

Tuesday March 15, 2022

SESSION 3 – DISRUPTIVE CONCEPTS AND METHODOLOGICAL INNOVATIONS IN NSCLC: MEET THE EXPERTS

 

Keynote Lecture

Advances in Lung Cancer

Solange Peters

President ESMO, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

 

Early stage lung cancer: challenge and opportunity

Haiquan Chen

Fudan University, Shanghai, China

 

Neoadjuvant and adjuvant strategies in NSCLC

Enriqueta Felip

Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

 

A focus on emerging paradigms in the treatment of early NSCLC

Jair Bar

Chaim Sheba Medical Center, Ramat Gan, Israel

 

IO in combination: the SPRING trial tri-therapy approach

Benjamin Solomon

Avera Cancer Institute, Sioux Falls, USA

 

New drugs for SCLC

Fiona Blackhall

The Christie and Manchester Cancer Research Centre, Manchester, UK

 

Coffee and Networking

SESSION 4 - WIN FIRST INTERNATIONAL MOLECULAR TUMOR BOARD: A STRATEGIC PLACE IN ADVANCING PRECISION ONCOLOGY

 

First WIN International Molecular Tumor Board

Introduction

Patients' cases presentation by investigators. Discussion and treatment recommendation

Moderator

Razelle Kurzrock

WIN Cosortium, Villejuif, France

 

Panel Discussion and Q&A from the audience

 

Lunch, poster viewing and networking

SESSION 5 – WHAT IS NEW IN BREAST, CRC, OVARY, HEAD & NECK, PROSTATE, KIDNEY, PEDIATRIC CANCERS?

 

Opening Keynote Lecture

The BIG AURORA molecular screening program for metastatic breast cancer: first results

Martine Piccart

Institut Jules Bordet, Brussels, Belgium

 

Keynote Lecture

Novel CRC insights based on combined genomic and
transcriptomic data at both bulk and single cell level, leading to new therapeutically relevant CRC classification

Sabine Tejpar

University of Leuven, Belgium

 

Serial profiling in metastatic CRC; beyond the tip of the
iceberg

Gerald Batist

Segal Cancer Centre, Lady Davis Institute at the JGH, McGill
University, Montréal, Canada

 

Paradigm shift in treatment of ovarian cancers

Susan Galbraith

AstraZeneca, USA

 

Novel strategies in head & neck cancers

Christophe Le Tourneau

Institut Curie, Paris, France

 

Expanding Precision Oncology across tumor types: advances in prostate cancer

Joaquín Mateo

Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

 

Pediatric European Precision Cancer Medicine Program -
Facing cancer complexity

Birgit Georger

Gustave Roussy, Villejuif, France
ITCC

 

BEST TWO POSTERS' PRESENTATIONS AND AWARDS

Josep Taberno, Vice-Chairman WIN Consortium, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Amir Onn, Head of Head of the Standard Operating Procedures and repository Committee WIN Consortium, Chair, Institute of Pulmonary Medicine, Sheba Medical Center, Israel

         

CONCLUSIONS

Richard L. Schilsky, Chairman WIN Consortium

 

Download the WIN 2022 Program

Download the Program Here

WIN 2022 Symposium
c/o MCI UK Ltd
Durford Mill
Petersfield
GU31 5AZ

Tel: +44 (0) 1730 715223
General enquiries: winsymposium@mci-group.com
Sponsorship enquiries: winsymposium@mci-group.com
Abstract enquiries: winsympabstracts@mci-group.com
Registration enquiries: winsympreghot@mci-group.com

View Our Privacy Policy Here